| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4760-5MG | Palbociclib (PD0332991) | 5mg | $105.00 | |
| GBM-4760-25MG | Palbociclib (PD0332991) | 25mg | $315.00 |
| Bioassays Specification | |
| Bio-Activity | CDK4 / CDK6 inhibitor |
| Chemical Name | 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-piperazin-1-yl)pyridine-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one |
| Function / Pharmacology | Potent and selective inhibitor of Cdk4, IC50 = 11 nM and Cdk6, IC50 = 16 nM.1 Inhibits phosphorylation of Rb protein and cell cycle progression through G1 in primary 5T33MM cells and sensitized these cells to killing by a proteasome inhibitor (bortezomib) in mouse models.2 Induces autophagy and senescence in AGS gastric cancer cells.3 Clinically useful breast cancer agent.4 Cell cycle inhibitors boost tumor immunogenicity.5 |
| CAS# | 571190-30-2 |
| MW | 447.53 |
| Molecular Formula | C24H29N7O2 |
| Solubility | Soluble in DMSO (up to 2 mg/ml with warming) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) El-Rayes et al. (2004), Cyclooxygenase-2-dependent and –independent effects of celecoxib in pancreatic cancer cell lines; Mol. Cancer Ther., 3 1427 2) Menu et al. (2008), A novel therapeutic combination using PD 0332991 and bortezomib: study in 5T33MM myeloma model; Cancer Res., 68 5519 3) Valenzuela et al. (2017), Palbociclib-induced autophagy and senescence in gastric cancer cells; Exp. Cell Res., 360 390 4) Palanisamy et al. (2016), Palbociclib: A new hope in the treatment of breast cancer; J. Cancer Res. Ther., 12 1220 5) Minton et al. (2017) Tumour immunology: Cell cycle inhibitors boost tumour immunogenicity; Nat. Rev. Immunol., 17 529 |
| Antibody Specification | |
| Alternate Names | PD-332991 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | CDK4 / CDK6 inhibitor |
| Chemical Name | 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-piperazin-1-yl)pyridine-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one |
| Function / Pharmacology | Potent and selective inhibitor of Cdk4, IC50 = 11 nM and Cdk6, IC50 = 16 nM.1 Inhibits phosphorylation of Rb protein and cell cycle progression through G1 in primary 5T33MM cells and sensitized these cells to killing by a proteasome inhibitor (bortezomib) in mouse models.2 Induces autophagy and senescence in AGS gastric cancer cells.3 Clinically useful breast cancer agent.4 Cell cycle inhibitors boost tumor immunogenicity.5 |
| CAS# | 571190-30-2 |
| MW | 447.53 |
| Molecular Formula | C24H29N7O2 |
| Solubility | Soluble in DMSO (up to 2 mg/ml with warming) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) El-Rayes et al. (2004), Cyclooxygenase-2-dependent and –independent effects of celecoxib in pancreatic cancer cell lines; Mol. Cancer Ther., 3 1427 2) Menu et al. (2008), A novel therapeutic combination using PD 0332991 and bortezomib: study in 5T33MM myeloma model; Cancer Res., 68 5519 3) Valenzuela et al. (2017), Palbociclib-induced autophagy and senescence in gastric cancer cells; Exp. Cell Res., 360 390 4) Palanisamy et al. (2016), Palbociclib: A new hope in the treatment of breast cancer; J. Cancer Res. Ther., 12 1220 5) Minton et al. (2017) Tumour immunology: Cell cycle inhibitors boost tumour immunogenicity; Nat. Rev. Immunol., 17 529 |
| Antibody Specification | |
| Alternate Names | PD-332991 |
| Protein Specification | |
| Purity | >98% |
